Bone Metastases - Cancer Network

NEWS

Cabozantinib Shows Promising Activity in Prostate Cancer Bone Metastases
August 24, 2011

ASCO 2011: Phase II Cabozantinib Trial in Patients with Advanced Solid Tumors and Bone Metastases
May 24, 2011

Denosumab, a RANK Ligand Inhibitor for Prevention of Skeletal-Related Events Due to Bone Metastases From Solid Tumors in Adults
ONCOLOGY Nurse Edition, April 18, 2011

Revised Guidelines on Metastatic Breast Cancer Bone Metastases
March 21, 2011

ASTRO Publishes Guidelines for Palliative Radiotherapy for Bone Metastases
February 18, 2011

JOB LISTINGS

Post a job

PRACTICE GUIDELINES

National Guideline Clearinghouse | Zoledronic acid for the treatment of bone metastases secondary to renal cell carcinoma.

www.guidelines.gov -

National Guideline Clearinghouse | ACR Appropriateness Criteria bone metastases.

www.guidelines.gov -

National Guideline Clearinghouse | American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

www.guidelines.gov -

CONNECT WITH US

	Become a fan on Facebook
	Add us on Google Plus
	Follow us on Twitter
	Sign up for our Newsletters
	Subscribe to our RSS Feed

Bone Metastases

Treatment for CRPC Patients With Bone Metastases

REVIEW ARTICLE
Kyle O. Rove, E. David Crawford; ONCOLOGY Vol. 25 No. 14
This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of PCa, and will weigh the clinical-outcomes evidence for and against their broad use.
• Managing CRPC: Improving Symptoms, Survival, or Both?
• Are We Trumping Bone Disease in Prostate Cancer?
Bone Biology and the Role of the RANK Ligand Pathway

REVIEW ARTICLE
Rashmi K. Murthy et al; ONCOLOGY Vol. 23 No. 14; Supplement
The goals of this article are to highlight the RANK ligand pathway and its involvement in healthy bone remodeling, bone metastasis, cancer treatment–induced bone loss, and multiple myeloma. Now and in the future, this topic will become even more important as novel therapies targeted at reducing skeletal complications emerge.
• Introduction: Skeletal Issues and Bone Health in Patients With Cancer
Metastatic Cancer in Solid Tumors and Clinical Outcome

REVIEW ARTICLE
Kyle O. Rove, E. David Crawford; ONCOLOGY Vol. 23 No. 14, Supplement
Advances in understanding the mechanisms of metastasis to bone, the resulting physiologic disturbances that take place, screening, diagnosis, and availability of better treatment options are advancing clinicians’ abilities to combat this devastating problem.
• Early Breast and Prostate Cancer and Clinical Outcomes (Fracture)
Early Breast and Prostate Cancer, Clinical Outcomes

REVIEW ARTICLE
Rowan T. Chlebowski, Tomoko Tagawa; ONCOLOGY Vol. 23 No. 14
All patients undergoing treatment for breast cancer and prostate cancer need evaluation of their state of bone health and fracture risk. If there is evidence of osteopenia or osteoporosis at baseline, secondary causes of bone loss should be excluded and a discussion of lifestyle modification factors, supplementation with calcium and vitamin D, and if appropriate, pharmacologic treatment needs to be initiated.

REVIEW ARTICLES

Evolution of Treatment Options for Patients With CRPC and Bone Metastases: Bone-Targeted Agents That Go Beyond Palliation of Symptoms to Improve Overall Survival
Kyle O. Rove, MD¹, E. David Crawford, MD¹ , December 31, 2011

This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of PCa, and will weigh the clinical-outcomes evidence for and against their broad use.
• Managing CRPC: Improving Symptoms, Survival, or Both?
• Are We Trumping Bone Disease in Prostate Cancer?

Early Breast and Prostate Cancer and Clinical Outcomes (Fracture)
Rowan T. Chlebowski, MD, PhD¹, Tomoko Tagawa, MD² , January 6, 2010

Over 40 million men and women in the United States have osteoporosis and low bone mineral density (BMD), placing them at risk for adverse skeletal events such as fractures and their sequelae. There are over 12 million cancer survivors in this country.

Bone Biology and the Role of the RANK Ligand Pathway
Rashmi K. Murthy, MD¹, P.K. Morrow, MD², Richard L. Theriault, MD³ , January 6, 2010

Bone renewal is essential for bone strength. During childhood and early adulthood, bone formation prevails over bone resorption, as bones increase in size and strength. Peak bone mass is achieved during the third decade in life, with a higher peak bone mass being protective against osteoporosis later in life.

Bone Disease in Multiple Myeloma
Matthew T. Drake, MD, PhD¹ , January 6, 2010

Despite the significant progress that has occurred in recent decades in the treatment of many advanced malignancies, skeletal morbidity remains a major problem for patients affected by cancers that metastasize to or grow primarily within bone.

Metastatic Cancer in Solid Tumors and Clinical Outcome: Skeletal-Related Events
Kyle O. Rove, MD¹, E. David Crawford, MD² , January 6, 2010

More than 50% of patients with advanced breast or prostate cancer have identifiable bone metastasis, and 30% to 40% of patients with non–small-cell lung cancer ultimately develop metastases to bone. Most tumors preferentially metastasize to the axial skeleton, targeting the vertebrae, pelvis, proximal ends of long bones, and skull.

MEDLINE

Bone Marrow Suppression by c-Kit Blockade Enhances Tumor Growth of Colorectal Metastases through the Action of Stromal Cell-Derived Factor-1.

pubmed.gov - 1/1/12

Background. Mobilization of c-Kit(+) hematopoietic cells (HCs) contributes to tumor vascularization. Whereas survival and proliferation of HCs are regulated by binding of the stem cell factor to its receptor c-Kit, migration of HCs is directed by stromal cell-derived factor (SDF)-1. Therefore, targeting migration of HCs provides a promising new strategy of anti-tumor therapy. Methods. BALB/c mice (n = 16) were pretreated with an anti-c-Kit antibody followed by implantation of CT26.WT-GFP colorectal cancer cells into dorsal skinfold chambers. Animals (n = 8) additionally received a neutralizing anti-SDF-1 antibody. Animals (n = 8) treated with a control antibody served as controls. Investigations were performed using intravital fluorescence microscopy, immunohistochemistry, flow cytometry and western blot analysis. Results. Blockade of c-Kit significantly enhanced tumor cell engraftment compared to controls due to stimulation of tumor cell proliferation and invasion without markedly

Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma.

pubmed.gov - 10/1/11

Bone is the most common site of metastases from nasopharyngeal carcinoma (NPC). Zoledronic acid (ZA) used to prevent skeletal-related events (SREs) of bone metastases has shown anti-tumor effects; yet, no report has been found on the survival benefit of ZA in NPC. This study aimed to evaluate whether ZA can bring survival benefits to patients with bone metastases from NPC.|A total of 307 patients with of NPC who had bone metastases were analyzed retrospectively. The differences of survival between patients treated with chemotherapy combined with ZA and those with chemotherapy alone were evaluated by the log-rank test. The Cox multivariate analyses of clinical features and different treatment methods of the 307 patients were conducted.|The prevalence of SREs in the combined approach group was lower than that with chemotherapy alone (34% vs. 48%, X (2)=7.003, P=0.008). The combined approach group had better progression-free survival (PFS) (11.5 vs. 5.5months, P<0.001) and

Vanishing bone metastases--a pitfall in the interpretation of contrast enhanced CT in patients with superior vena cava obstruction.

pubmed.gov - 9/1/11

We describe a previously unreported case of vertebral marrow enhancement owing to collateral circulation in a patient with superior vena cava obstruction. Failure to recognise this phenomenon led to the misdiagnosis of sclerotic bone metastases.

Cryotreatment against metastatic renal cell bone tumour reduced multiple lung metastases.

pubmed.gov - 9/1/11

Metastatic renal cell carcinoma (RCC) has a poor response to anticancer chemotherapy and radiotherapy. While immunotherapy and molecular targeted drugs have been used as first-line therapy for RCC metastasis, the response rate to these agents is low. We report the case of a patient with lung and bone metastases of RCC whose lung metastases disappeared after reconstruction using the resected specimen treated by liquid nitrogen for the bone metastasis. This 60-year-old female had a left RCC with multiple lung metastases and a left femoral bone metastasis at the time of diagnosis. After left nephrectomy followed by immunotherapy, we performed tumour excision and reconstruction with frozen recycled autograft. The lung metastases had disappeared by 10 months after surgery, while serum levels of interferon-gamma and interleukin-12 had increased. We postulate that the antitumour activity resulted from immunotherapy plus cryotreatment of her bone metastasis and believe that this case supports

Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.

pubmed.gov - 9/1/11

Introduction: Denosumab, a fully human monoclonal antibody, targets the receptor activator of nuclear factor-kappaB (RANK) ligand, a protein essential for osteoclast differentiation, activity and survival. Loss of osteoclasts from the bone surface reduces bone turnover and bone loss in malignant and benign diseases. In breast cancer, bone metastases are frequently observed; cancer treatment-induced bone loss (CTIBL) may result as a consequence of endocrine treatment or chemotherapy. Furthermore, preclinical studies suggest a direct role of the RANK/RANK-ligand pathway in breast tumorigenesis. This paper reviews preclinical and clinical data on denosumab in breast cancer.Materials and methods: Studies were identified through the Medline database. Key search terms included: AMG-162, bisphosphonates, denosumab, RANK-ligand and zoledronic acid. Information available in abstract form only was retrieved from major oncology meetings, such as the American Society of Clinical Oncology (ASCO)

Result Pages: 1 2 3 4 5 6 Next